INCY · Incyte Corporation
$95.932026-05-17Sector: Healthcare; Industry: Biotechnology; Sub-Industry: Biotechnology
Intrinsic Value Range Comparison · Mulya.ai
R&D capitalized (5yr)Bull
$253
+163.6% vs market
Base · active
$180
+87.3% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($173 · $253) Analysts Range ($84 · $135) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $3.0B | — | 29.7% | 0.0% | $1.5B | −$291MM | $1.2B | 6.6% | — | 25.3% | $5.8B | $4.63 | — |
| 2022.Q4 | $3.4B | 13.7% | 24.5% | 35.6% | $536MM | −$151MM | $386MM | 7.8% | — | 9.1% | $5.9B | $1.66 | — |
| 2023.Q4 | $3.7B | 8.9% | 24.5% | 28.4% | $649MM | −$611MM | $38MM | 7.6% | — | 10.5% | $6.4B | $2.92 | — |
| 2024.Q4 | $4.2B | 14.8% | 2.6% | 45.0% | $61MM | −$566MM | −$505MM | 8.2% | — | 0.8% | $9.1B | $0.16 | — |
| 2025.Q4 | $5.1B | 21.2% | 36.6% | 22.7% | $1.5B | −$1.0B | $426MM | 8.1% | — | 17.4% | $7.6B | $6.28 | 10.4 |
| italics below = DCF projection · 10yr Rev CAGR: 5.4% |
| 2026.Q4 | $5.6B | +8.4% | 37.5% | 22.4% | $1.6B | −$656MM | $964MM | 7.3% | $898MM | 20.5% | $8.2B | $5.69 | 16.9 |
| 2027.Q4 | $6.2B | +11.5% | 44.3% | 22.2% | $2.1B | −$1.0B | $1.1B | 7.5% | $984MM | 24.5% | $9.2B | $7.53 | 12.7 |
| 2028.Q4 | $6.5B | +4.4% | 36.6% | 21.9% | $1.9B | −$447MM | $1.4B | 7.6% | $1.1B | 19.6% | $9.7B | $6.51 | 14.7 |
| 2029.Q4 | $6.8B | +4.4% | 22.1% | 21.6% | $1.2B | −$479MM | $694MM | 7.7% | $519MM | 11.8% | $10.2B | $4.12 | 23.3 |
| 2030.Q4 | $7.1B | +4.3% | 22.1% | 21.4% | $1.2B | −$513MM | $715MM | 7.8% | $495MM | 11.8% | $10.7B | $4.31 | 22.3 |
|
| Term. Yr+ | $9.0B | 4.1% | 38.4% | 20.0% | $2.8B | −$867MM | $1.9B | 8.6% | $19.7B | 13.1% | — | — | — |
Active scenario IV: $180 (+87.3% vs market)